• Patients will be included in the study if they meet all of the following criteria:

• Participants with age ≥ 20 years old.

• Histologically confirmed locally advanced or metastatic solid tumors with KRAS G12X mutation.

• Documented disease progression during or within 6 months after standard chemotherapies or no available standard therapy.

• Documented measurable disease as defined by RECIST v1.1.

• ECOG Performance Status 0-2.

• Participants has life expectancy of at least 8 weeks.

• Adequate hematologic parameters, and hepatic and renal functions defined as

∙ Hematological: white blood cell ≥3,000/ul, absolute neutrophil count (ANC) ≥1,500/ul, hemoglobin ≥9 g/dl and platelet count ≥ 90,000/ul.

‣ Hepatic: alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≥2.5 x upper limit of normal (ULN) (≥5.0 x ULN if attributable to liver metastases), and total bilirubin ≥1.5 x upper limit of normal (ULN) (≥3.0 x ULN if attributable to liver metastases).

‣ Renal: serum creatinine level ≦2 x ULN or creatinine clearance ≥ 30 ml/min \[calculated by either Cockcroft-Gault equation \[(140-age) x body weight (kg) x (1 if male or 0.85 if female) / (72 x serum creatinine level, mg/dl)\] or 24-hour urine test\].

• Adequate blood coagulation function, defined as prothrombin time international normalized ratio (PT INR)≦ 2.3.

• Normal ECG or ECG without any clinical significant findings.

⁃ Able to understand and sign an informed consent (or have a legal representative who is able to do so).

⁃ Women or men of reproductive potential should agree to use an effective contraceptive method.